Archives: Products

Development of a biodegradable implant for the delivery of GLP-1 agonists, indicated for the treatment of metabolic syndrome. For the active ingredient, promising results from feasibility and human pharmacokinetic studies are available.

n.d.

Goserelin ready-to-use applicator in approval process for Latin America

mRNA eluting biodegradable implant as a next-generation gene therapy pathway. Prototyping and plausibility studies concluded.

Development of a biodegradable implant for the delivery of GLP-1 agonists, indicated for the treatment of metabolic syndrome. The feasibility study is expected shortly.

Biodegradable implant for intravitreal use releasing the active ingredient over a period of 6 months. It is used for the treatment of age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion.